Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Inmaculada Sanchez‐Simon"'
Autor:
Karthick Vishwanathan, Inmaculada Sanchez‐Simon, Bhumsuk Keam, Nicolas Penel, Maria deMiguel‐Luken, Doris Weilert, Andrew Mills, Marcelo Marotti, Martin Johnson, Alain Ravaud
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 4, Pp n/a-n/a (2020)
Abstract Osimertinib is a third‐generation, irreversible, oral epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR‐TKI sensitizing and EGFR T790M and has demonstrated efficacy
Externí odkaz:
https://doaj.org/article/3def02ff83134171b001fbbb4b3c90e2
Autor:
Panagiotis Kourtesis, Inmaculada Sanchez-Simon, Sandip Pravin Patel, Mayukh Das, Susana Banerjee, Alfonso Cortés Salgado, Jennifer R. Diamond, Maria Libera Ascierto, Amit M. Oza, Ana Oaknin
Publikováno v:
Ovarian cancer.
Introduction/Background The immune checkpoints NKG2A and programmed cell death-1 (PD-1) are expressed on both tumour-infiltrating natural killer (NK) and CD8+ T cells in several cancer types, and are implicated in reducing antitumor immune response.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44ca02a344364f5965a51ee94997867c
https://doi.org/10.1136/ijgc-2020-esgo.147
https://doi.org/10.1136/ijgc-2020-esgo.147
Autor:
Nicolas Penel, Karthick Vishwanathan, Alain Ravaud, Bhumsuk Keam, Martin Johnson, Inmaculada Sanchez-Simon, Maria de Miguel-Luken, Doris Weilert, Andrew Mills, Marcelo Marotti
Publikováno v:
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives, Vol 8, Iss 4, Pp n/a-n/a (2020)
Pharmacology Research & Perspectives, Vol 8, Iss 4, Pp n/a-n/a (2020)
Osimertinib is a third‐generation, irreversible, oral epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR‐TKI sensitizing and EGFR T790M and has demonstrated efficacy in non
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36dfb55310a91895d57f00b9e21d0c92
https://doi.org/10.1002/prp2.613
https://doi.org/10.1002/prp2.613
Autor:
Carmen Kahatt, Luis Paz-Ares, Inmaculada Sanchez-Simon, Elizabeth Jimenez Aguilar, Rafael Nuñez, Santiago Ponce Aix, Sonia Extremera, Alejandro Falcon Gonzalez, Jesus R Fernandez, Elena Brehcist, Julia Martinez, Ali Zeaiter, Gregory M. Cote
Publikováno v:
Journal of Clinical Oncology. 39:5586-5586
5586 Background: LUR is a new agent that exerts antitumor activity through inhibition of trans-activated transcription and modulation of tumor microenvironment. Preclinical synergism/additivity in combination with IRI has been reported, thus promptin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37cabd0c59397a6e279a56598da1af54
https://doi.org/10.1200/jco.2021.39.15_suppl.5586
https://doi.org/10.1200/jco.2021.39.15_suppl.5586
Autor:
Elizabeth Jimenez Aguilar, Santiago Ponce Aix, Gregory M. Cote, Eva Maria Gonzalez, Juan Manuel Sepúlveda, Luis Paz-Ares, Mariano Siguero, Ali Zeaiter, Monica Insa, Inmaculada Sanchez-Simon, Maria Jose Flor, Rafael Nuñez, Martin Cullell-Young, Alejandro Gonzalez, Carmen Kahatt
Publikováno v:
Journal of Clinical Oncology. 38:3514-3514
3514 Background: LUR is a novel agent that exerts antitumor activity through inhibition of trans-activated transcription and modulation of tumor microenvironment. Preclinical synergism/additivity in combination with IRI has been reported, thus prompt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::331f732465d7c48d89db0057ae5d1ade
https://doi.org/10.1200/jco.2020.38.15_suppl.3514
https://doi.org/10.1200/jco.2020.38.15_suppl.3514
Autor:
Alejandro Falcon, Roberto Lasso, Catalina Marquez, Inmaculada Sanchez-Simon, Maria Pilar Sancho Marquez, Ana Fernandez-Teijeiro, Manuel Noguer, Javier Martin Broto, Nadia Hindi
Publikováno v:
Journal of Clinical Oncology. 34:e22509-e22509
e22509Background: High-dose methotrexate (HDMTX) is a backbone of systemic therapy of osteosarcoma along with cisplatin and doxorubicin. Children excrete MTX more effectively than adults and on thi...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9eac4f3207c8c6cc76f450e5afb1acc
https://doi.org/10.1200/jco.2016.34.15_suppl.e22509
https://doi.org/10.1200/jco.2016.34.15_suppl.e22509
Autor:
L. Jiménez González-Serna, Alejandro Falcon, Inmaculada Sanchez-Simon, Juan Antonio Virizuela, A. Cervera, A Gutierrez-Valencia, M. Cruz, FL Lopez-Cortes, CM Rosso-Fernandez, B. Pérez-Valderrama, E Martinez-Lozano, I. Gallego Jiménez, Nadia Hindi, Luis Paz-Ares, J Martinez-Atienza, P. Maíquez, Marta Espinosa, Ignacio Duran, A. Rodríguez
Publikováno v:
Journal of Clinical Oncology. 34:227-227
227 Background: A.A has been approved for the treatment of mCRPC before and after docetaxel. The standard regime consists on daily A.A. 1.000 mg in a fasting state along with prednisone 10mg q.d. However, data from pharmacokinetic (PK) studies in pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07e8179525472c14f4dd79b63f1c7d9f
https://doi.org/10.1200/jco.2016.34.2_suppl.227
https://doi.org/10.1200/jco.2016.34.2_suppl.227
Autor:
Angela Araujo Miguez, Frank Nieboer, Iris Simon, Rocio Garcia-Carbonero, Fernando de la Portilla, Inmaculada Sanchez-Simon, Juan M. Bozada, Lisette Stork
Publikováno v:
Journal of Clinical Oncology. 32:501-501
501 Background: ColoPrint is a gene expression classifier that has demonstrated improved prognostic accuracy over conventional clinical and pathological factors in patients with stage II-III CRC (Salazar et al, JCO 2011). MSI-Print is a gene classifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec87aba293d0b68700e18d501fc9d21c
https://doi.org/10.1200/jco.2014.32.3_suppl.501
https://doi.org/10.1200/jco.2014.32.3_suppl.501